Clinical trial · Interventional
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
NCT04949191CI-TRIAL-00080588terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): A business decision due to availability of commercial drug and other options for accessing study drug treatment.
Summary
Brief summary (as posted)
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
| Pemigatinib | Drug | Pemigatinib | ALIAS |
| Retifanlimab | Drug | Retifanlimab | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Study Treatment 1: Pemigatinib (INCB054828)
- description
- Pemigatinib will be taken orally once daily
- interventionNames
- Drug: Pemigatinib
- type
- EXPERIMENTAL
- label
- Study Treatment 2: Pemigatininb+ Retifanlimab
- description
- Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks
- interventionNames
- Drug: Pemigatinib
- Drug: Retifanlimab
- type
- EXPERIMENTAL
- label
- Study Treatment 3: Pemigatininb + Pembrolizumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol) of pemigatinib as monotherapy or combination therapy. * Currently benefiting from and tolerating treatment with pemigatinib, as determined by the investigator. * Demonstrated compliance, as assessed by the investigator, with the parent protocol requirements. * Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures. * Currently have no evidence of progressive disease, as determined by the investigator, following treatment with pemigatinib as monotherapy or combination therapy. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Able to access pemigatinib commercially or outside of a clinical trial. * Permanently discontinued from the parent protocol for any reason. * No longer meet the inclusion/exclusion criteria from the parent protocol if still receiving treatment. * Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study.
References
Publications (0)
Data not yet available
No reference posted for this study.